Sinopharm Group Co. Ltd. (1099.HK)
HKD 21.45
(-1.15%)
HKD 21.45
(-1.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 22.31 Billion CNY | -1.92% |
| 2022 | 20.6 Billion CNY | 4.53% |
| 2021 | 19.71 Billion CNY | 10.99% |
| 2020 | 17.75 Billion CNY | 10.06% |
| 2019 | 16.13 Billion CNY | 4.81% |
| 2018 | 15.39 Billion CNY | 29.32% |
| 2017 | 11.9 Billion CNY | 16.57% |
| 2016 | 10.21 Billion CNY | 10.91% |
| 2015 | 9.2 Billion CNY | 17.3% |
| 2014 | 7.85 Billion CNY | 29.09% |
| 2013 | 6.08 Billion CNY | 25.05% |
| 2012 | 4.86 Billion CNY | 33.75% |
| 2011 | 3.63 Billion CNY | 50.95% |
| 2010 | 2.4 Billion CNY | 55.38% |
| 2009 | 1.55 Billion CNY | 32.26% |
| 2008 | 1.17 Billion CNY | 48.49% |
| 2007 | 789.34 Million CNY | 64.36% |
| 2006 | 480.25 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q4 | 12.48 Billion CNY | 260.35% |
| 2023 FY | 20.2 Billion CNY | -1.92% |
| 2023 Q3 | 3.46 Billion CNY | -64.76% |
| 2023 Q2 | 9.83 Billion CNY | 0.0% |
| 2022 Q4 | 8.01 Billion CNY | 126.92% |
| 2022 FY | 20.6 Billion CNY | 4.53% |
| 2022 Q2 | 9.51 Billion CNY | 0.0% |
| 2022 Q3 | 3.53 Billion CNY | -62.87% |
| 2021 FY | 19.71 Billion CNY | 10.99% |
| 2021 Q4 | 11.91 Billion CNY | 0.0% |
| 2021 Q2 | 9.07 Billion CNY | 0.0% |
| 2020 FY | 17.75 Billion CNY | 10.06% |
| 2020 Q2 | 7.58 Billion CNY | 0.0% |
| 2020 Q4 | 11.52 Billion CNY | 0.0% |
| 2019 Q4 | 9.86 Billion CNY | 0.0% |
| 2019 Q2 | 8.31 Billion CNY | 0.0% |
| 2019 FY | 16.13 Billion CNY | 4.81% |
| 2018 Q2 | 7.18 Billion CNY | 0.0% |
| 2018 FY | 15.39 Billion CNY | 29.32% |
| 2018 Q4 | 8.22 Billion CNY | 0.0% |
| 2017 Q1 | 2.54 Billion CNY | -48.83% |
| 2017 Q4 | 7.24 Billion CNY | 0.0% |
| 2017 FY | 11.9 Billion CNY | 16.57% |
| 2017 Q2 | 5.87 Billion CNY | 130.5% |
| 2016 Q4 | 4.98 Billion CNY | 0.0% |
| 2016 FY | 10.21 Billion CNY | 10.91% |
| 2016 Q2 | 5.21 Billion CNY | 0.0% |
| 2015 FY | 9.2 Billion CNY | 17.3% |
| 2015 Q4 | 4.59 Billion CNY | 0.0% |
| 2015 Q2 | 4.61 Billion CNY | 0.0% |
| 2014 FY | 7.85 Billion CNY | 29.09% |
| 2014 Q2 | 3.91 Billion CNY | 0.0% |
| 2014 Q4 | 3.94 Billion CNY | 0.0% |
| 2013 Q2 | 2.99 Billion CNY | 0.0% |
| 2013 Q4 | 3.08 Billion CNY | 0.0% |
| 2013 FY | 6.08 Billion CNY | 25.05% |
| 2012 Q4 | 1.25 Billion CNY | 18.84% |
| 2012 FY | 4.86 Billion CNY | 33.75% |
| 2012 Q3 | 1.05 Billion CNY | 0.0% |
| 2012 Q2 | 1.05 Billion CNY | 0.0% |
| 2012 Q1 | 1.05 Billion CNY | 0.0% |
| 2011 Q4 | 1.05 Billion CNY | 31.26% |
| 2011 Q3 | 804.78 Million CNY | 0.0% |
| 2011 Q1 | 804.78 Million CNY | 0.0% |
| 2011 Q2 | 804.78 Million CNY | 0.0% |
| 2011 FY | 3.63 Billion CNY | 50.95% |
| 2010 Q2 | 531.24 Million CNY | 0.0% |
| 2010 FY | 2.4 Billion CNY | 55.38% |
| 2010 Q1 | 531.24 Million CNY | 0.0% |
| 2010 Q3 | 531.24 Million CNY | 0.0% |
| 2010 Q4 | 804.78 Million CNY | 51.49% |
| 2009 Q4 | 531.24 Million CNY | 44.38% |
| 2009 FY | 1.55 Billion CNY | 32.26% |
| 2009 Q2 | 367.95 Million CNY | 0.0% |
| 2009 Q3 | 367.95 Million CNY | 0.0% |
| 2009 Q1 | 367.95 Million CNY | 0.0% |
| 2008 FY | 1.17 Billion CNY | 48.49% |
| 2008 Q4 | 367.95 Million CNY | 9.56% |
| 2008 Q3 | 335.84 Million CNY | 0.0% |
| 2008 Q2 | 335.84 Million CNY | 0.0% |
| 2008 Q1 | 335.84 Million CNY | 0.0% |
| 2007 Q2 | 242.81 Million CNY | 0.0% |
| 2007 Q3 | 242.81 Million CNY | 0.0% |
| 2007 Q4 | 335.84 Million CNY | 38.31% |
| 2007 FY | 789.34 Million CNY | 64.36% |
| 2007 Q1 | 242.81 Million CNY | 0.0% |
| 2006 Q3 | 116.37 Million CNY | 0.0% |
| 2006 Q4 | 242.81 Million CNY | 108.65% |
| 2006 FY | 480.25 Million CNY | 0.0% |
| 2006 Q1 | 116.37 Million CNY | 0.0% |
| 2006 Q2 | 116.37 Million CNY | 0.0% |
| 2005 Q4 | 116.37 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Wanjia Group Holdings Limited | -15.4 Million HKD | 145006.421% |
| China Health Group Limited | -36.11 Million HKD | 61903.52% |
| Tai United Holdings Limited | -344.16 Million HKD | 6584.765% |